María Del Mar Figueroa Gispert

Ms. María Del Mar Figueroa Gispert

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Cells
Verified
Journal Article
Open access
PDF file
María Del Mar Figueroa GispertMaría Del Mar Figueroa Gispert
María Del Mar Figueroa Gispert
CRClaudia Marie Ramos-Lugo
Claudia Marie Ramos-Lugo
COCarlimar Ocasio-Malavé
Carlimar Ocasio-Malavé
RSRizaldy P. Scott
Rizaldy P. Scott
JAJared Tyler Ahrendsen
Jared Tyler Ahrendsen
AEAna M Espino
Ana M Espino
Ulcerative colitis (UC) is the most prevalent inflammatory bowel disease (IBD) in the USA. Current treatments present clinical limitations, underscoring the need for innovative therapeutics that promote an anti-inflammatory immune response. This study evaluates the anti-inflammatory potential of Fh15, a recombinant Fasciola hepatica fatty acid binding protein, in a DSS-induced UC mouse model. Our results demonstrated that Fh15 treatment significantly ameliorated the severity of colitis by reducing the disease activity index (DAI) and histopathological scores. Moreover, Fh15 also decreased the serum levels of myeloperoxidase (MPO) and chitinase-3-like protein 1 (CHI3L1), and the expression of S100A9, a calcium and zinc binding protein, which is an important marker for the pathogenesis of UC. Furthermore, Fh15 downregulated pro-inflammatory cytokines TNFα and IL-1β in the distal colon, suggesting modulation of macrophage activity. Immunohistochemistry analysis revealed significantly reduced neutrophil and macrophage infiltration in UC Fh15-treated mice. These findings highlight the therapeutic potential of Fh15 for UC, as it modulates inflammatory responses, reduces leukocyte infiltration, and preserves colon integrity.

5 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
María Del Mar Figueroa GispertMaría Del Mar Figueroa Gispert
María Del Mar Figueroa Gispert
CRClaudia Marie Ramos-Lugo
Claudia Marie Ramos-Lugo
COCarlimar Ocasio-Malavé
Carlimar Ocasio-Malavé
RSRizaldy P Scott
Rizaldy P Scott
JAJared Tyler Ahrendsen
Jared Tyler Ahrendsen
AEAna M Espino
Ana M Espino
Ulcerative colitis (UC) is the most prevalent inflammatory bowel disease (IBD) in the USA. Current treatments present clinical limitations, underscoring the need for innovative therapeutics that promote an anti-inflammatory immune response. This study evaluates the anti-inflammatory potential of Fh15, a recombinant Fasciola hepatica fatty acid binding protein in a DSS-induced UC mouse model. Our results demonstrated that Fh15 treatment significantly ameliorated the severity of colitis by reducing the disease activity index (DAI) and histopathological scores. Moreover, Fh15 also decreased serum levels of myeloperoxidase (MPO), and chitinase-3-like protein 1 (CHI3L1), and the expression of S100A9, a calcium-and zinc binding protein, which is an important marker for the pathogenesis of UC. Furthermore, Fh15 downregulated pro-inflammatory cytokines TNFα and IL-1β in the distal colon, suggesting modulation of macrophage activity. Immunohistochemistry analysis revealed significantly reduced neutrophil and macrophage infiltration in UC Fh15-treated mice. These findings highlight the therapeutic potential of Fh15 for UC, as it modulates inflammatory responses, reduces leukocyte infiltration, and preserves colon integrity.

20 May 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RRRiseilly Ramos-Nieves
Riseilly Ramos-Nieves
AAAlbersy Armina-Rodriguez
Albersy Armina-Rodriguez
María Del Mar Figueroa GispertMaría Del Mar Figueroa Gispert
María Del Mar Figueroa Gispert
GFGhalib Figueroa-Quiñones
Ghalib Figueroa-Quiñones
COCarlimar Ocasio-Malavé
Carlimar Ocasio-Malavé
AEAna M Espino
Ana M Espino
Background/Objectives: In the past, FhSAP-2, an 11.5 kDa recombinant protein belonging to the Fasciola hepatica saposin-like/NK-lysin family, has been shown to induce over 60% partial protection in immunized rabbits and mice when challenged with F. hepatica metacercariae. However, despite FhSAP-2 being a promising vaccine candidate, its hydrophobic nature has made its purification a challenging process. The present study aimed to determine whether a modified 9.8 kDa variant of protein (mFhSAP-2), lacking a string of 16 hydrophobic amino acids at the amino terminus and a dominant Th1 epitope, could retain its immunogenic and Th1-inducing properties. Methods: RAW264.7 cells were stimulated with mFhSAP-2, and TNFα levels were determined. C57BL/6 mice were immunized with mFhSAP-2 alone or emulsified with Montanide ISA50. Total anti-mFhSAP-2 IgG subtypes, along with their avidity and titers, were measured using ELISA. The T cell proliferation index and levels of CD4+/CD8+ and IFNγ/IL-4 ratios were determined. Results: In vitro, mFhSAP-2 induced dose-dependent TNFα production in RAW264.7 cells. In vivo, mice immunized with mFhSAP-2 or mFhSAP-2+ISA50 developed high-avidity IgG2a and IgG2c antibodies at levels that were significantly higher than IgG1 antibody levels. However, the mFhSAP-2+ISA50 formulation induced higher and more homogenous antibody titers than mFhSAP-2, suggesting that an adjuvant may be required to enhance mFhSAP-2 immunogenicity. Immunization with mFhSAP-2+ISA50 also induced significantly higher activated CD4+/CD8+ T cell ratios and IFNγ/IL-4 ratios compared to naïve mice. Conclusions: Our results demonstrate that mFhSAP-2 retained its immunogenicity and Th1-polarizing properties, which were enhanced by the Montanide ISA50 adjuvant. The present study highlights the feasibility of inducing Th1-associated immune responses in mice using mFhSAP-2 as an antigen. Further studies are required to assess the potential application of the mFhSAP-2+ISA50 formulation as a vaccine against F. hepatica in natural hosts such as cattle and sheep, which could contribute to improved control and aid in the prevention and eradication of F. hepatica infection.

10 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RRRiseilly Ramos-Nieves
Riseilly Ramos-Nieves
AAAlbersy Armina-Rodriguez
Albersy Armina-Rodriguez
María Del Mar Figueroa GispertMaría Del Mar Figueroa Gispert
María Del Mar Figueroa Gispert
GFGhalib Figueroa-Quiñones
Ghalib Figueroa-Quiñones
COCarlimar Ocasio-Malavé
Carlimar Ocasio-Malavé
AEAna M Espino
Ana M Espino
Background/Objectives: FhSAP-2 is a 11.5kDa recombinant protein belonging to the Fasciola hepatica saposin-like/NK-lysin protein family. It has shown to induce partial protection >60% (reduction in parasite burden and parasite egg output) against F. hepatica challenge infection when delivered subcutaneously in rabbits and mice, either emulsified in Freund’s adjuvant or as inclusion bodies. The protection induced by FhSAP-2 was associated with increased levels of IgG2a and IFNγ. However, despite FhSAP-2 being a promising vaccine candidate, its hydrophobic character has made its purification a challenged process. The present study aimed to determine whether a modified 9.8kDa variant of protein (mFhSAP-2), lacking the string of 15 hydrophobic amino acids at amino terminus containing a dominant Th1-epitope, could retain its immunogenic and Th1-inducing properties. Methods: RAW264.7 cells were stimulated with mFhSAP-2, and levels of TNFα were determined. C57BL6 mice were immunized with mFhSAP-2 alone or emulsified with Montanide ISA50. Levels of each specific anti-mFhSAP-2 IgG subtypes, their avidity and titers were measured by ELISA. T-cell proliferation index as well as levels of CD4+/CD8+ and IFNγ /IL-4 ratios were determined. Results: In vitro, mFhSAP-2 induced dose-dependent TNFα production in RAW264.7 cells. In vivo, mice immunized with mFhSAP-2 alone induced 1.76-fold higher than IgG2a and 1.28-fold higher than IgG1, whereas mice immunized with mFhSAP-2+ISA50 developed 2.16-fold more IgG2c than IgG2a and 1.49-fold more IgG2c than IgG1. All mice developed high-avidity IgG2a and IgG2c antibodies. Mice immunized with mFhSAP-2+ISA50 developed higher IgG2a and IgG2c titers (1:6,400 and 1:25,600, respectively) than those immunized with mFhSAP-2 alone (1:1,600 and 1:3,200, respectively). Immunization with mFhSAP-2+ISA50 also induced significantly high activated CD4+/CD8+ T-cells and IFNγ/IL-4 ratios. Conclusions: Our results showed that mFhSAP-2 retained its immunogenicity and Th1-polarizing properties, which were enhanced by Montanide ISA-50 adjuvant.

Verified
Journal Article
Open access
PDF file
María Del Mar Figueroa GispertMaría Del Mar Figueroa Gispert
María Del Mar Figueroa Gispert
Natalie M. Meléndez-VázquezNatalie M. Meléndez-Vázquez
Natalie M. Meléndez-Vázquez
AEAna M Espino
Ana M Espino
FGFilipa Godoy-Vitorino
Filipa Godoy-Vitorino
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by dysbiosis of the gut microbiota. Helminth infections are known to modulate host immunity and intestinal microbial composition; however, the therapeutic use of live parasites poses safety challenges. The recombinant Fasciola hepatica fatty acid-binding protein Fh15 is a helminth-derived molecule with anti-inflammatory effects in models of septic shock and dextran sulfate sodium (DSS)-induced colitis. Whether Fh15 also influences gut microbial composition during colitis remains unknown. Male C57BL/6 mice received 4% DSS in drinking water for 7 days to induce colitis and were treated intraperitoneally with Fh15 (2 mg/kg) on days 1, 3, and 5. Fecal samples were collected on days 2, 4, and 7 for 16S rRNA gene sequencing. Standard microbiota pipelines were used to evaluate community diversity. Acute DSS treatment disrupted gut microbial diversity and community structure compared with non-colitic controls. Fh15 treatment partially restored early microbial balance by shifting microbial composition toward that of healthy mice and reducing microbial dispersion, indicating enhanced community stability despite severe dysbiosis. Although alpha diversity did not return to control levels, Fh15 mitigated the expansion of pro-inflammatory genera (Enterococcus and Turicibacter) and preserved beneficial taxa, including Adlercreutzia.